Total Debt Summary of Intervacc AB (publ)

Intervacc AB (publ)'s latest annual total debt in 2023 was 181 Thousand SEK , down -43.79% from previous year.
Intervacc AB (publ)'s latest quarterly total debt in 2024 Q2 was 124 Thousand SEK , down -6.77% from previous quarter.
Intervacc AB (publ) reported annual total debt of 322 Thousand SEK in 2022, down -25.64% from previous year.
Intervacc AB (publ) reported annual total debt of 433 Thousand SEK in 2021, up 13.05% from previous year.
Intervacc AB (publ) reported quarterly total debt of 133 Thousand SEK for 2024 Q1, down -26.52% from previous quarter.
Intervacc AB (publ) reported quarterly total debt of 162 Thousand SEK for 2023 Q2, down -6.36% from previous quarter.

Annual Total Debt Chart of Intervacc AB (publ) (2023 - 2013)

Historical Annual Total Debt of Intervacc AB (publ) (2023 - 2013)

Year	Total Debt	Total Debt Growth
2023	181 Thousand SEK	-43.79%
2022	322 Thousand SEK	-25.64%
2021	433 Thousand SEK	13.05%
2020	383 Thousand SEK	-48.52%
2019	744 Thousand SEK	-29.94%
2018	1.06 Million SEK	-87.57%
2017	8.54 Million SEK	-64.16%
2016	23.84 Million SEK	30.65%
2015	18.25 Million SEK	-3.36%
2014	18.88 Million SEK	0.0%
2013	- SEK	0.0%

Year	Total Debt	Total Debt Growth
2024 Q2	124 Thousand SEK	-6.77%
2024 Q1	133 Thousand SEK	-26.52%
2023 Q2	162 Thousand SEK	-6.36%
2023 FY	181 Thousand SEK	-43.79%
2023 Q4	181 Thousand SEK	19.08%
2023 Q1	173 Thousand SEK	-46.27%
2023 Q3	152 Thousand SEK	-6.17%
2022 Q3	193 Thousand SEK	-4.46%
2022 Q1	212 Thousand SEK	-51.04%
2022 FY	322 Thousand SEK	-25.64%
2022 Q2	202 Thousand SEK	-4.72%
2022 Q4	322 Thousand SEK	66.84%
2021 FY	433 Thousand SEK	13.05%
2021 Q1	157 Thousand SEK	-59.01%
2021 Q4	433 Thousand SEK	254.92%
2021 Q3	122 Thousand SEK	-12.86%
2021 Q2	140 Thousand SEK	-10.83%
2020 Q2	215 Thousand SEK	-41.89%
2020 Q1	370 Thousand SEK	-50.27%
2020 Q3	192 Thousand SEK	-10.7%
2020 FY	383 Thousand SEK	-48.52%
2020 Q4	383 Thousand SEK	99.48%
2019 FY	744 Thousand SEK	-29.94%
2019 Q2	361 Thousand SEK	-38.81%
2019 Q4	744 Thousand SEK	136.19%
2019 Q3	315 Thousand SEK	-12.74%
2019 Q1	590 Thousand SEK	-44.44%
2018 Q2	870.14 Thousand SEK	-0.91%
2018 FY	1.06 Million SEK	-87.57%
2018 Q4	1.06 Million SEK	35.76%
2018 Q3	782.23 Thousand SEK	-10.1%
2018 Q1	878.09 Thousand SEK	-89.72%
2017 Q3	2.74 Million SEK	6.2%
2017 Q4	8.54 Million SEK	211.13%
2017 FY	8.54 Million SEK	-64.16%
2017 Q1	6.77 Million SEK	-71.59%
2017 Q2	2.58 Million SEK	-61.82%
2016 Q4	23.84 Million SEK	0.0%
2016 Q1	- SEK	0.0%
2016 FY	23.84 Million SEK	30.65%
2015 FY	18.25 Million SEK	-3.36%
2014 FY	18.88 Million SEK	0.0%
2013 FY	- SEK	0.0%

Peer Total Debt Comparison of Intervacc AB (publ)

Name	Total Debt	Total Debt Difference
Alligator Bioscience AB (publ)	16.09 Million SEK	98.876%
Ziccum AB (publ)	857 Thousand SEK	78.88%
Modus Therapeutics Holding AB (publ)	- SEK	-Infinity%
BioArctic AB (publ)	4.97 Million SEK	96.365%
Sprint Bioscience AB (publ)	- SEK	-Infinity%
Mendus AB (publ)	24.48 Million SEK	99.261%
Genovis AB (publ.)	79.32 Million SEK	99.772%
QuiaPEG Pharmaceuticals Holding AB (publ)	20.61 Million SEK	99.122%
Active Biotech AB (publ)	3 Million SEK	93.967%
Magle Chemoswed Holding AB (publ)	60.3 Million SEK	99.7%
Bio-Works Technologies AB (publ)	- SEK	-Infinity%
Aptahem AB (publ)	5 Million SEK	96.38%
Vicore Pharma Holding AB (publ)	- SEK	-Infinity%
Kancera AB (publ)	- SEK	-Infinity%
Infant Bacterial Therapeutics AB (publ)	- SEK	-Infinity%
Fluicell AB (publ)	- SEK	-Infinity%
Saniona AB (publ)	71.4 Million SEK	99.747%
Lipigon Pharmaceuticals AB (publ)	- SEK	-Infinity%
Biovica International AB (publ)	7.82 Million SEK	97.688%
Spago Nanomedical AB (publ)	- SEK	-Infinity%
AcouSort AB (publ)	- SEK	-Infinity%
Xintela AB (publ)	- SEK	-Infinity%
Abliva AB (publ)	424 Thousand SEK	57.311%
Egetis Therapeutics AB (publ)	108.6 Million SEK	99.833%
Karolinska Development AB (publ)	3.07 Million SEK	94.104%
OncoZenge AB (publ)	- SEK	-Infinity%
Amniotics AB (publ)	2.58 Million SEK	92.984%
2cureX AB (publ)	- SEK	-Infinity%
CombiGene AB (publ)	- SEK	-Infinity%
Asarina Pharma AB (publ)	1 Million SEK	81.9%
Calliditas Therapeutics AB (publ)	979.13 Million SEK	99.982%
Camurus AB (publ)	24.5 Million SEK	99.261%
Corline Biomedical AB	- SEK	-Infinity%
IRLAB Therapeutics AB (publ)	27.56 Million SEK	99.343%
Isofol Medical AB (publ)	- SEK	-Infinity%
I-Tech AB	- SEK	-Infinity%
Hansa Biopharma AB (publ)	866.76 Million SEK	99.979%
Cyxone AB (publ)	858 Thousand SEK	78.904%
ExpreS2ion Biotech Holding AB (publ)	1.71 Million SEK	89.421%
Biosergen AB	- SEK	-Infinity%
Cantargia AB (publ)	- SEK	-Infinity%
NextCell Pharma AB	- SEK	-Infinity%
Xspray Pharma AB (publ)	36.8 Million SEK	99.508%
Elicera Therapeutics AB (publ)	- SEK	-Infinity%
Nanologica AB (publ)	666 Thousand SEK	72.823%
SynAct Pharma AB	637 Thousand SEK	71.586%
Annexin Pharmaceuticals AB (publ)	- SEK	-Infinity%
Stayble Therapeutics AB (publ)	850 Thousand SEK	78.706%
LIDDS AB (publ)	- SEK	-Infinity%
Lipum AB (publ)	1.76 Million SEK	89.722%
BioInvent International AB (publ)	23.24 Million SEK	99.221%
Alzinova AB (publ)	800 Thousand SEK	77.375%
Oncopeptides AB (publ)	106.48 Million SEK	99.83%
Pila Pharma AB (publ)	773.08 Thousand SEK	76.587%
Guard Therapeutics International AB (publ)	- SEK	-Infinity%
Scandinavian ChemoTech AB (publ)	- SEK	-Infinity%
Simris Alg AB (publ)	90.74 Million SEK	99.801%
Diamyd Medical AB (publ)	30.67 Million SEK	99.41%
Xbrane Biopharma AB (publ)	231.47 Million SEK	99.922%
Ascelia Pharma AB (publ)	1.06 Million SEK	82.941%
Diagonal Bio AB (publ)	- SEK	-Infinity%

Global Stocks Search

Intervacc AB (publ) (IVACC.ST)

Total Debt Summary of Intervacc AB (publ)

Annual Total Debt Chart of Intervacc AB (publ) (2023 - 2013)

Historical Annual Total Debt of Intervacc AB (publ) (2023 - 2013)

Peer Total Debt Comparison of Intervacc AB (publ)